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Abstract
Diuretics are considered the first-line pharmacological treatment option for ascites. 
Diuretic treatment begins with spironolactone and furosemide. Non-pharmacological 
options include salt restriction, large-volume paracentesis (LVP), transjugular intrahe-
patic portosystemic shunt (TIPS), and peritoneovenous shunt. Ascites can be mobilized 
if renal sodium excretion tops 78 mmol daily (88 mmol–10 mmol daily) after restrict-
ing sodium intake to 88 mmol/day (about 2000 mg/day). The majority of patients with 
cirrhotic ascites respond to a combination of sodium restriction and diuretics such as 
spironolactone and furosemide (90%). Ascites that does not respond to sodium restric-
tion and high-dose diuretic treatment (400 mg/day of spironolactone and 160 mg/day 
of furosemide) or following paracentesis is labeled refractory. Refractory ascites can be 
managed with large-volume paracentesis or transjugular intrahepatic portosystemic 
shunt. Peritoneovenous shunting is considered as a third-line treatment option after all 
other measures such as diuretics, large-volume paracentesis, or transjugular intrahepatic 
portosystemic shunt deemed unsuccessful or contraindicated. It has a high rate of shunt 
obstruction.
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1. Introduction
According to the European Association for the Study of the Liver [1], management of ascites 
is based on grading and the patient’s clinical presentation. Grade 1 ascites (mild ascites iden-
tified by ultrasound) require no treatment. Grade 2 ascites (moderate ascites with moderate 
abdominal distention) require sodium restriction and diuretics. Grade 3 ascites (gross ascites 
with marked abdominal distention) necessitate large-volume paracentesis (LVP) followed 
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by both sodium restriction and diuretics. In addition, treatment depends on the underlying 
cause. Ascites with high serum-ascites albumin gradient (SAAG) is caused by portal hyper-
tension and is managed with sodium restriction and diuretics [2]. On the contrary, treatment 
of ascites with low SAAG is achieved by managing the causative pathology [2]. In this chap-
ter, the role for non-pharmacological therapeutic options such as sodium restriction, paracen-
tesis, transjugular intrahepatic portosystemic shunt (TIPS), and peritoneovenous shunt (PVS) 
in the management of ascites will be discussed (Table 1).
2. Dietary sodium restriction
In ascites, the decreased sodium excretion leads to a positive sodium balance [3]. Dietary sodium 
restriction, along with diuretics, is considered the first-line treatment options for patients with 
cirrhotic ascites [2]. Limiting sodium intake to 88 mmol/day (about 2000 mg/day) is recom-
mended [4]. Cirrhotic patients without fever or diarrhea have about less than 10 mmol of 
non-renal sodium excretion daily [5]. Ascites can be mobilized if renal sodium excretion tops 
78 mmol daily (88 mmol–10 mmol daily) [2]. Adherence to dietary sodium restriction can be 
assessed by 24-hour urinary sodium, random urinary sodium concentrations, or urine sodium/
potassium ratio [2]. A urine sodium/potassium ratio >1 with no evidence of weight loss indicates 
nonadherence [6]. Unfortunately, only 10–20% of the patients improve with sodium restriction, 
necessitating the additional use of diuretics for better mobilization of ascites [3]. Moreover, strict 
limitations of sodium intake may exacerbate the already existing state of malnutrition these 
patients already have [7].
3. Large-volume paracentesis
Nearly 90% of patients with cirrhotic ascites respond to a combination of sodium restriction 
and diuretics (spironolactone and furosemide) [8]. About 5–10% become refractory to the 
abovementioned treatment [9]. Ascites that does not respond to sodium restriction and high-
dose diuretic treatment (400 mg/day of spironolactone and 160 mg/day of furosemide) or 
Treatment Comment
1 Salt restriction • First-line therapy along with diuretics
2 LVP • Needs albumin infusion to prevent PICD
3 TIPS •  Encephalopathy is the main complication
•  High patency rate with PTFE-coated stent
•  Proper selection prevents hepatic decompensation
4 PVS •  Very limited use in clinical practice
•  High occlusion rate
Table 1. Non-pharmacological therapy for ascites due to liver cirrhosis.
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following paracentesis is labeled refractory [10]. Patients who require more than three admis-
sions annually have recurrent ascites [11]. Moreover, patients with refractory ascites have a 
low average survival rate of about 6 months [12]. Patients with either refractory ascites or 
grade 3 ascites require LVP [12]. LVP is a procedure performed in the office-based setting by 
inserting a needle in the left iliac fossa or by inserting a peritoneal drain for duration of 3 days 
[12, 13]. Of notice, there is no increased risk of spontaneous bacterial peritonitis (SBP) with 
the latter method [14]. Quintero et al. concluded that removal of 5 l of ascites by paracentesis 
in patients with pitting edema caused the fluid to shift from the periphery and redistribute 
[15]. Moreover, both Gentile et al. [16] and Pinto et al. [17] agreed on the safety of tapping 5 l 
of ascetic fluid without the hemodynamic changes that follow the procedure, such as a drop 
in diastolic pressure, aldosterone release, and decreased sodium excretion. With large-volume 
paracentesis alone, decreased blood volume more than 3 hours after paracentesis is expected 
to happen as right atrial pressure, Pulmonary capillary wedge pressure (PCWP), and cardiac 
output markedly drop [18]. Removing a considerable amount of ascetic fluid increases the 
risk for paracentesis-induced circulatory dysfunction (PICD) [19]. PICD is associated with 
increased mortality rate at 6 months [20]. Administering 8 g of intravenous albumin/liter of 
ascetic fluid removed prevents paracentesis-induced circulatory dysfunction (PICD) follow-
ing drainage of more than 5 l of ascetic fluid [1, 6, 21]. Gines et al. evaluated the role of IV 
albumin administration in patients who underwent LVP. Only 2% of patients who received 
IV albumin experienced renal dysfunction and hyponatremia in contrast to those who did not 
receive IV albumin (21%) [21]. In PICD, vasodilation leads to activation of the renin-angio-
tensin system in an attempt to restore systemic vascular resistance [22]. Renal dysfunction, 
vasopressin release and water retention, hypervolemic hyponatremia, and underfilling are 
consequences [22]. Interestingly, using 4 g (half the dose) of IV albumin in prevention of PICD 
was as effective as using 8 g [23]. Studies also reported the role of terlipressin, a V1 receptor 
agonist, as a vasoconstrictor in preventing the neurohumoral responses following paracente-
sis [24, 25]. Moreau et al. compared the actions of both IV albumin and terlipressin in inhib-
iting arterial vasodilation, and both were found to be effective [24]. In contrast to albumin, 
terlipressin is much cheaper [24].
4. Transjugular intrahepatic portosystemic shunt
TIPS could be a substitute for LVP in patients who require more than three LVPs monthly or 
those with recurrent ascites [12]. In TIPS, a communication is created between the portal and 
outflow hepatic veins, aiming at lowering portal venous pressure and subsequent activation of 
renin-angiotensin system [26]. Ascites usually resolves without the need for diuretics or sodium 
restriction following TIPS insertion, as patients easily excrete sodium; however, diuretics may be 
needed for few months after TIPS placement [27–29]. Moreover, norepinephrine, plasma renin, 
and aldosterone activities decrease following TIPS insertion, leading to improved renal func-
tion in patients with cirrhosis [27–29]. The main indication for TIPS in cirrhotic patients is acute 
variceal bleeding not responding to endoscopic and medical therapy, refractory ascites, or for 
secondary prevention of gastric variceal bleeding [2]. Several studies compared the role of TIPS 
to LVP with IV albumin infusion. Unfortunately, the results of the studies showed that patients 
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with TIPS insertion had a worse prognosis in patients with refractory ascites [30–33]. This may 
be explained by poor patient selection for TIPS. However, patients who have TIPS insertion with 
polytetrafluoroethylene (PTFE)-covered stents had better outcomes and stent patency compared 
to those with bare-metal stents [34, 35]. Model for end-stage liver disease (MELD) is a scoring sys-
tem for evaluating the severity of chronic liver disease. It was developed initially to predict the 3 
months of mortality in patients who had undergone a TIPS procedure [36] and was subsequently 
adopted for prioritizing receipts on the waiting list for liver transplantation [37, 38].
High MELD score [39] and bilirubin levels >3 mg/dl [40, 41] increase mortality rates in patients 
who had TIPS placement; therefore, good selection of candidates for TIPS is very important 
for good outcome. Hepatic encephalopathy is the main complication encountered in 25–30% 
of patients who undergo TIPS, especially older patients [41, 42]. TIPS is contraindicated in 
patients with severe pulmonary hypertension, portal thrombosis, heart failure, and advanced 
liver disease (Child-Pugh class C) [3].
5. Peritoneovenous shunts
PVS can be used in the treatment of refractory ascites that needed multiple LVPs or patients 
who cannot have TIPS placement or liver transplantation [13, 43]. In PVS, a one-way valve 
tube is created to allow movement of ascites from the positively pressured peritoneum 
to the superior vena cava through the internal jugular vein in the negatively pressured 
chest cavity [44]. If central venous pressure gets elevated, the flow is hindered [3]. Most 
common complication encountered with PVS is obstruction of the shunt [45]. Coagulation 
disorders, severe cardiac or kidney failure, and loculated ascites are contraindications 
for PVS [13]. Moreover, PVS is not frequently used due to lack of survival benefit and 
low shunt patency rate [46, 47]. In addition, sepsis and SBP prompt shunt removal [43]. 
The abovementioned leaves PVS with very limited use in clinical practice as a treatment 
option after all other measures such as diuretics, LVP, and TIPS deemed unsuccessful or 
 contraindicated [43, 48, 49].
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